GVAX cancer vaccine consisting of patient cells modified to contain the gene for GM-CSF data

SOMA (Alameda, Calif.) reported Phase I data in 10 patients, with safety and an immune response demonstrated to the patients' own cells engineered with the gene for GM-CSF. ...